AL Amyloidosis Market 2026 Market Size And Growth Forecast: Key Trends To Watch
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
AL Amyloidosis Market Size And Revenue Outlook Through 2030
The al amyloidosis market size has experienced swift expansion in recent years. It is anticipated to increase from $3.51 billion in 2025 to $3.97 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. The growth observed in prior periods stemmed from various factors, including a scarcity of treatment options, a reliance on conventional chemotherapy, limited disease awareness, insufficient organ-specific supportive care, and restricted access to specialized treatment centers.
The al amyloidosis market size is anticipated to experience substantial expansion over the coming years. It is projected to reach $6.38 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. This growth during the forecast period is attributed to several factors, including the development of innovative targeted therapies, the increasing adoption of monoclonal antibodies and proteasome inhibitors, the expansion of stem cell transplant programs, the improvement of healthcare infrastructure for rare diseases, and enhanced diagnostic technologies for early detection. Key trends during this period are expected to encompass the growing uptake of targeted therapies for al amyloidosis, the rising application of monoclonal antibodies and proteasome inhibitors, the broadening of stem cell transplant procedures, an increasing emphasis on organ-specific supportive care, and greater awareness leading to earlier diagnosis of al amyloidosis.
Get A Free Sample Report With In-Depth Market Insights:
AL Amyloidosis Market Growth Backed By Core Demand Fundamentals
An increasing occurrence of plasma cell disorders is anticipated to fuel the expansion of the AL amyloidosis market in the future. These disorders involve aberrant plasma cells generating an excess of atypical antibodies, which can lead to harm to organs. The growing prevalence of plasma cell disorders stems from elements like an older demographic, extended lifespans, and improved diagnostic methods. AL amyloidosis is a disease originating from plasma cell disorders, particularly characterized by the excessive creation of abnormal light chain proteins. This process results in the buildup of amyloid deposits within organs and tissues, intensifying the consequences of plasma cell dyscrasias. As an illustration, reports from The American Cancer Society (ACS), a US-based nonprofit, indicated in August 2024 that for 2024, approximately 35,780 new multiple myeloma cases are predicted (comprising 19,520 for men and 16,260 for women), with an estimated 12,540 deaths (7,020 among men and 5,520 among women). Consequently, the increased occurrence of plasma cell disorders is stimulating the expansion of the AL amyloidosis market.
AL Amyloidosis Market Segmentation And Category Overview
The al amyloidosis market covered in this report is segmented –
1) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy
2) By Drugs: Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs
3) By Route Of Administration: Intravenous, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
Subsegments:
1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy
2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)
3) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
4) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors
AL Amyloidosis Market Growth Trends Reshaping The Competitive Landscape
Leading companies operating in the AL amyloidosis market are dedicated to developing innovative treatments, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, with the goal of improving therapeutic efficacy and patient outcomes. Next-generation BCMA-directed CAR T-cell therapy is defined as an advanced form of immunotherapy that involves engineering a patient’s T cells to precisely target and attack BCMA found on the surface of cancer cells, specifically those associated with multiple myeloma. For example, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for NXC-201 to treat the life-threatening blood disorder known as Amyloid Light Chain (AL) Amyloidosis. NXC-201 is a next-generation CAR-T cell therapy currently undergoing clinical trials for the treatment of amyloid light chain (AL) amyloidosis, exhibiting promising results with a 100% hematologic response rate and improvements in organ function for patients who had previously failed other treatments.
AL Amyloidosis Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the al amyloidosis market are Johnson & Johnson, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Novartis AG, Merck & Co. Inc., Eli Lilly and Company, GlaxoSmithKline plc, Genmab A/S, Prothena Corporation plc, BridgeBio Pharma Inc., Oncopeptides AB, Ionis Pharmaceuticals Inc., Neurimmune AG, Immix Biopharma Inc., Attralus Inc.
View The Full AL Amyloidosis Market Report:
AL Amyloidosis Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the AL amyloidosis market in 2025. The regions covered in the al amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
